| 6.16 0.18 (3.01%) | 04-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.5 | 1-year : | 7.89 |
| Resists | First : | 6.42 | Second : | 6.76 |
| Pivot price | 6.3  |
|||
| Supports | First : | 5.88 | Second : | 4.89 |
| MAs | MA(5) : | 6.08 |
MA(20) : | 6.29 |
| MA(100) : | 5.16 |
MA(250) : | 4.31 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 18.3 |
D(3) : | 20.6 |
| RSI | RSI(14): 51 |
|||
| 52-week | High : | 6.76 | Low : | 3.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ADMA ] has closed above bottom band by 33.4%. Bollinger Bands are 18.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.25 - 6.29 | 6.29 - 6.32 |
| Low: | 5.82 - 5.86 | 5.86 - 5.91 |
| Close: | 6.09 - 6.16 | 6.16 - 6.22 |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Wed, 10 Apr 2024
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Tue, 09 Apr 2024
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now? - Yahoo Finance
Thu, 04 Apr 2024
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment? - Simply Wall St
Wed, 03 Apr 2024
Rising Margins And Product Promise Drive ADMA Biologics Forward (NASDAQ:ADMA) - Seeking Alpha
Mon, 01 Apr 2024
Investors in ADMA Biologics (NASDAQ:ADMA) have seen splendid returns of 261% over the past three years - Yahoo Finance
Tue, 26 Mar 2024
A Closer Look at 6 Analyst Recommendations For ADMA Biologics - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 228 (M) |
| Shares Float | 224 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 77.4 (%) |
| Shares Short | 7,290 (K) |
| Shares Short P.Month | 6,720 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | -11 % |
| Operating Margin | 19.2 % |
| Return on Assets (ttm) | 4.5 % |
| Return on Equity (ttm) | -19.7 % |
| Qtrly Rev. Growth | 47.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.13 |
| EBITDA (p.s.) | 0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 9 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -47.39 |
| PEG Ratio | 0 |
| Price to Book value | 10.26 |
| Price to Sales | 5.44 |
| Price to Cash Flow | 159.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|